Article

Potent and specific human monoclonal antibodies against SARS-CoV-2 Omicron variant by rapid mRNA immunization of humanized mice

2022-03-18

Abstract excerpt

The Omicron variant (B.1.1.529) of SARS-CoV-2 rapidly becomes dominant globally. Its extensive mutations confer severe efficacy reduction to most of existing antibodies or vaccines. Here, we developed RAMIHM , a highly efficient strategy to generate fully human monoclonal antibodies (mAbs), directly applied it with Omicron-mRNA immunization, and isolated three potent and specific clones against Omicron. Rapid mRN...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: ba6f77aa-7fcd-5b9c-be34-a8aed5ee8932
DOI: 10.1101/2022.03.17.484817

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Potent and specific human monoclonal antibodies against SARS-CoV-2 Omicron variant by rapid mRNA immunization of humanized miceDOI 10.1101/2022.03.17.484817Read

Atlas of Currently-Available Human MAbs and Escape to Newly-Emerging Omicron BA.1/BA.1.1/BA.2/BA.3Semantic proximity Read

In-Silico Analysis of Monoclonal Antibodies against SARS-CoV-2 Omicron.Semantic proximity Read

Atlas of currently available human neutralizing antibodies against SARS-CoV-2 and escape by Omicron sub-variants BA.1/BA.1.1/BA.2/BA.3Semantic proximity Read

Function and Cryo-EM structures of broadly potent bispecific antibodies against multiple SARS-CoV-2 Omicron sublineagesSemantic proximity Read

Updated Atlas of Currently Available Human Neutralizing Antibodies Against SARS-CoV-2 and Escape by Omicron Sub-Variants BA.2.12.1/BA.2.13/BA.4/BA.5Semantic proximity Read

Production of a monoclonal antibody targeting the SARS-CoV-2 Omicron spike protein and analysis of SARS-CoV-2 Omicron mutations related to monoclonal antibody resistance.Semantic proximity Read

An updated atlas of antibody evasion by SARS-CoV-2 Omicron sub-variants including BQ.1.1 and XBBSemantic proximity Read

Structural delineation and computational design of SARS-CoV-2-neutralizing antibodies against Omicron subvariantsSemantic proximity Read

Preclinial Safety and Efficacy of a Therapeutic Antibody That Targets SARS-CoV-2 at the Sotrovimab Face But is Escaped by OmicronSemantic proximity Read

Reduced B-Cell Antigenicity of Omicron Lowers Host Serologic ResponseSemantic proximity Read

SARS-CoV-2 Omicron: Viral Evolution, Immune Evasion, and Alternative Durable Therapeutic Strategies.Semantic proximity Read

Combating the SARS-CoV-2 Omicron (BA.1) and BA.2 with potent bispecific antibodies engineered from non-Omicron neutralizing antibodiesSemantic proximity Read